COMMISSION IMPLEMENTING REGULATION (EU) 2024/2745

| Official Journal of the European Union | EN L series ---|---|--- * * * | 2024/2745 | 28.10.2024 ---|---|--- COMMISSION IMPLEMENTING REGULATION (EU) 2024/2745 of 25 October 2024 laying down rules for the application of Regulation (EU) 2021/2282 of the European Parliament and of the Council as regards the management of conflicts of interest in the joint work of the Member State Coordination Group on Health Technology Assessment and its subgroups (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU (1), and in particular Article 5(7) and Article 25(1), point (a), thereof, Whereas: (1) | Regulation (EU) 2021/2282 lays down a support framework and procedures for cooperation between Member States on health technologies at Union level and establishes the Member State Coordination Group on Health Technology Assessment (‘the Coordination Group’). ---|--- (2) | In accordance with Regulation (EU) 2021/2282, the members of the Coordination Group and its subgroups are to appoint their representatives who are individuals, on an ad hoc or permanent basis (‘representatives’). ---|--- (3) | Regulation (EU) 2021/2282 provides for the involvement of patients, clinical experts and other relevant experts (‘individual experts’) in joint clinical assessments and joint scientific consultations. Those experts are to be selected for their expertise in the therapeutic area concerned and act in individual capacity rather than representing any organisation, institution, or Member State. ---|--- (4) | The conflicts of interests for the assessment of which the Commission is to lay down rules in accordance with Regulation (EU) 2021/2282, concern the conflicts of interests of the representatives and the individual experts in the health technology developers’ industrial sector, who participate in the joint work of the Coordination Group and its subgroups carried out pursuant to Articles 7 to 22 of Regulation (EU) 2021/2282 (‘the joint work’). The management of conflicts of interest of other individuals who might be involved in the joint work by the members of the Coordination Group and its subgroups remains within the responsibility of the Member States who are to ensure that these individuals have no financial or other interests in the health technology developers’ industrial sector which could affect their independence or impartiality. ---|--- (5) | The relevant activities with regard to the management of conflicts of interest in the Coordination Group and its subgroups should encompass the activities related to the conduct of joint clinical assessments and joint scientific consultations, including where individual experts take part in this joint work, the development of methodological guidance on joint work and the preparation of reports on emerging health technologies. ---|--- (6) | For the representatives appointed to the Coordination Group or its subgroups, the participation in the joint work should be subject to the submission to the Commission of a signed declaration of interests (‘DOI’) and a curriculum vitae (‘CV’). For the individual experts, their ability to be selected for and to take part in a joint clinical assessment or a joint scientific consultation should be subject to the submission to the Commission of a signed DOI and a CV. When deciding on conflicts of interest in accordance with Article 28, point (b), of Regulation (EU) 2021/2282, the Commission should assess the interests declared in the DOI and the information in the CV of the representative or the individual expert. In case of failure to declare an interest, appropriate measures should be taken. ---|--- (7) | In accordance with Regulation (EU) 2021/2282, the DOI is to be updated annually and whenever necessary. To ensure that the activities of the Coordination Group and its subgroups are carried out in an independent, impartial and transparent manner at any point in time, it should be specified that an update is necessary whenever there is a change in the information provided by the representative or individual expert. To reduce administrative burden, the representative or the individual expert should be able to confirm the information submitted in the DOI where no change in the declared interest has occurred. Where such confirmation is not provided in due time, the representative or the individual expert should no longer participate in the joint work. ---|--- (8) | To ensure a uniform approach regarding the interests to be declared and a proper management of the conflicts of interest in the joint work, it is appropriate to set out rules on the content, format and the validity of the DOI, as well as the rules on its submission. As the joint work under Regulation (EU) 2021/2282 is to be conducted in parallel and in close cooperation with the European Medicines Agency and with the expert panels referred to in Article 106(1) of Regulation (EU) 2017/745 of the European Parliament and of the Council (2), the DOI employed in the respective legal frameworks should be aligned as far as possible while preserving the separation of the respective remits of the Coordination Group, the European Medicines Agency and these expert panels. ---|--- (9) | Pursuant to Article 30(3), points (a) and (b), of Regulation (EU) 2021/2282 and in order to ensure the robustness of the system of the management of conflicts of interest and the highest standards of independence, impartiality and transparency related to the joint work, the DOI of the representatives of the Coordination Group and its subgroups and of clinical experts and other relevant experts involved in the joint work should be made publicly available. The DOI of patients should not be made publicly available. The DOI should be published only so far as necessary to achieve these aims. In particular, the DOI of the representatives of the Coordination Group and its subgroups should be made publicly available for the period of their involvement in the joint work. The DOI of clinical experts and other relevant experts involved in the joint work should be made publicly available for one year after the finalisation of the joint work in which they participated. ---|--- (10) | Pursuant to Article 5(2) of Regulation EU 2021/2282, interests that could affect the independence or impartiality of the representatives and individual experts are financial or other interests in the health technology developers’ industrial sector. Therefore, it is necessary to define such interests. Moreover, a conflict of interest may arise not only because of the current links to the health technology developers’ industrial sector, but also because of the links in the recent past and in the near future. In order to reduce administrative burden and ensure legal certainty, it is appropriate to define the time periods after which it should be considered that the link no longer gives rise to a conflict of interest. ---|--- (11) | To ensure legal certainty, rules should be established for the assessment of the submitted DOI and the deadlines within which the assessment is to be completed or within which additional information is to be provided. ---|--- (12) | At the moment of the assessment by the Commission of the interests declared by the representatives in their DOI, it is not always possible to establish conflicts of interest, as the specific health technology developer or specific health technology with respect to which a conflict of interest might exist might not be under assessment in the Coordination Group or its subgroups at that time. It is not always possible to establish conflicts of interest even where the health technology is already being assessed by the Coordination Group or its subgroups, as a conflict of interest might exist due to the link with the comparator health technology, which might not be yet known at the time of the assessment of the interests declared by the representatives or individual experts in their DOI. Therefore, the Commission should also decide on potential conflicts of interest of the representatives and of the individual experts. Thus, where the relevant situations of conflict of interest arise, the actions to be taken are known without the need for the supplementary assessment by the Commission. ---|--- (13) | In addition to conflicts or potential conflicts of interest that are readily identifiable, there may be situations of appearance of a conflict of interest. In particular, the roles and responsibilities of the chair and co-chair of the Coordination Group and its subgroups should be considered incompatible with certain interests in the past, as those interests may give rise to doubts about the independence and impartiality of the chair or co-chair. Therefore, it is appropriate to provide for cooling-off periods for the roles and responsibilities of the chair and co-chair of the Coordination Group and its subgroups. ---|--- (14) | To ensure appropriate access to the relevant expertise, the applicable measures in case of a conflict or potential conflict of interest should vary depending on the declared interest and the roles and responsibilities of the representative or individual expert. They should exclude or limit the participation of the representative or individual expert in the joint work. The Commission acting as secretariat of the Coordination Group (‘the HTA secretariat’) should be responsible for the enforcement of the imposed exclusions from, or limitations of the participation in the joint work. ---|--- (15) | Under Regulation (EU) 2021/2282, the relevant subgroup is to ensure that individual experts are given the opportunity to provide their input during joint clinical assessments and joint scientific consultations. It is necessary to reconcile, on the one hand, the twofold requirement of independence and impartiality of individual experts, as laid down in Article 5(2) of Regulation (EU) 2021/2282, and, on the other hand, the public interest, referred to in Articles 8(6), 10(4), 18(6) and 18(7) of that Regulation, relating to the need for the relevant in-depth specialised expertise in order to ensure the highest scientific quality of the joint work. Therefore where in exceptional cases, for example, for rare diseases, only individual experts with conflicts of interests within the meaning of this Regulation that have such expertise are available, the Commission may propose to the relevant subgroup the appropriate involvement in the joint work of such individual experts considering their conflicts of interest, while ensuring transparency pursuant to Article 5(5) of Regulation (EU) 2021/2282. ---|--- (16) | In order to ensure good management of conflict of interest, the members of the Coordination Group and its subgroups should be required to notify the HTA secretariat any changes of their representatives. ---|--- (17) | Within its specific scope relating to the management of conflicts of interest in the joint work of the Coordination Group and its subgroups, this Regulation lays down, in accordance with Article 5(1), point (a), of Regulation (EU) 2018/1725 of the European Parliament and of the Council (3), the rules for processing, through the IT platform, as defined in Article 30 of Regulation (EU) 2021/2282 (‘the HTA IT platform’), personal data for the purposes of ensuring that the joint work of the Coordination Group and its subgroups under Regulation (EU) 2021/2282 is carried out in an independent, impartial and transparent manner. In particular, it should be ensured that the representatives and individual experts participating in the joint work are free from conflicts of interest with regard to the health technology developers’ industrial sector which could affect their independence or impartiality. ---|--- (18) | This Regulation should specify the personal data that may be processed for the defined purposes, namely personal data included in the DOI and CV. It should determine that the Commission is to be considered the controller within the meaning of Article 3, point (8), of Regulation (EU) 2018/1725 for the processing of this data through the HTA IT platform. In order to ensure the possibility to verify whether the joint work was conducted in an independent and impartial manner, notably in the event of complaints or litigation, it is appropriate to provide for a retention period of personal data and for its review at regular intervals. ---|--- (19) | The identity of the patient may reveal the patient’s health status in relation to the subject-matter of the joint clinical assessment or the joint scientific consultation. Therefore, that type of data should be considered a special category of personal data under Article 10 of Regulation (EU) 2018/1725, and the processing of such data should be made conditional on the fulfilment of the criteria laid down in Article 10(2), point (i), of that Regulation, including the set-up of suitable and specific measures to safeguard the rights and freedoms of the data subject, in particular professional secrecy. ---|--- (20) | The Commission should make the information about the data processing available on the publicly accessible webpage of the HTA IT platform so that the categories of data subjects whose personal data is being processed can be informed of their rights under Chapter III of Regulation (EU) 2018/1725, as well as the means by which they can exercise those rights. ---|--- (21) | As Regulation (EU) 2021/2282 applies with effect from 12 January 2025, this Regulation should also apply from that date. ---|--- (22) | The European Data Protection Supervisor was consulted in accordance with Article 42 of Regulation (EU) 2018/1725 and delivered an opinion on 5 July 2024. ---|--- (23) | The measures provided for in this Regulation are in accordance with the opinion of the Committee on Health Technology Assessment, ---|--- HAS ADOPTED THIS REGULATION: Article 1 Submission of the DOI 1\. Before submitting a signed declaration of interests (‘DOI’) to the Commission and until the Commission has assessed the declared interests in accordance with Article 4, the representatives appointed to the Coordination Group and its subgroups referred to in Article 5(3) of Regulation (EU) 2021/2282 (‘representatives’) may not do any of the following: (a) | access the parts of the secure system of the IT platform, as defined in Article 30 of Regulation (EU) 2021/2282 (‘the HTA IT platform’) relevant for the performance of their tasks; ---|--- (b) | take up the roles and responsibilities of a chair or a co-chair in the Coordination Group or its subgroups; ---|--- (c) | take up the roles and responsibilities of an assessor or a co-assessor for a joint clinical assessment or a joint scientific consultation; ---|--- (d) | attend meetings of the Coordination Group or its subgroups for conducting joint clinical assessments, joint scientific consultations, developing methodological guidance for joint work or for preparing reports on emerging health technologies. ---|--- 2\. Before submitting a signed declaration of interests (‘DOI’) to the Commission and until the Commission has assessed the declared interest in accordance with Article 4, patients, clinical experts and other relevant experts referred to in Article 5(5) of Regulation (EU) 2021/2282 (‘individual experts’) may not be selected and take part in a joint clinical assessment or a joint scientific consultation and may not access the parts of the secure system of the HTA IT platform relevant for the performance of their tasks. Article 2 Content of the DOI 1\. Representatives and individual experts shall declare in the DOI all financial or other interests, whether of direct or indirect nature, in the health technology developers’ industrial sector, by answering the standard questions listed in the DOI form set out in Annex I to this Regulation. Representatives or individual experts who answer to the questions in the affirmative shall provide further details in the respective sections of the DOI form. 2\. Representatives and individual experts shall assume full responsibility in relation to the content of the DOI submitted. Article 3 Format of the DOI 1\. The DOI of a representative or individual expert shall be submitted digitally through the HTA IT platform in the form set out in Annex I and shall be accompanied by a comprehensive curriculum vitae (‘CV’) of the representative or of the individual expert based on the Europass CV template. The DOI shall be deemed submitted only if it is duly completed, signed, and accompanied by such CV. 2\. When an interest declared in the DOI referred to in paragraph 1 has changed, an updated DOI shall be submitted without undue delay in accordance with the procedure set out in paragraph 1. Article 4 Assessment of information submitted in the DOI 1\. The Commission shall assess the interests declared in the DOI, as well as the information in the CV of the representative or the individual expert, submitted in accordance with Article 3. 2\. If necessary, the Commission may request that the representative or the individual expert submit any additional information needed for the assessment of the declared interests. The representative or the individual expert shall provide that information within 10 days from the day of the notification of the request. 3\. Where no further information is needed for the assessment of the declared interests, the Commission shall complete the assessment within 15 working days from the submission of the DOI in accordance with Article 3. 4\. If the Commission decides that the declared interest does not constitute a conflict or potential conflict of interest within the meaning of Annex II, the representative or the individual expert may participate in the joint work. 5\. If the Commission decides that the declared interest constitutes a conflict or potential conflict of interest within the meaning of Annex II, Articles 6, 7 and 8 shall apply. Article 5 Validity and publication of DOI 1\. The DOI shall be valid as long as the representative or the individual expert is involved in the joint work if: (a) | no change in the declared interest has occurred; ---|--- (b) | information referred to in point (a) has been confirmed by the representative or the individual expert by the end of each year starting on the day on which the DOI was submitted in accordance with Article 3(1) or (2). Where such confirmation is not provided, the HTA secretariat shall ensure that the representative or the individual expert is no longer involved in the joint work. ---|--- 2\. The DOI and the information on the qualifications and areas of relevant expertise from the accompanying CVs of the representatives shall be made available on the publicly accessible webpage of the HTA IT platform for the period of their involvement in the joint work. 3\. The DOI and the information on the qualifications and areas of relevant expertise from the accompanying CVs of clinical experts and other relevant experts shall be made available on the publicly accessible webpage of the HTA IT platform for one year after the finalisation of the joint work in which they participated. Article 6 Action with regard to conflicts or potential conflicts of interest of the representatives 1\. If the Commission decides, in accordance with Article 28, point (b), of Regulation (EU) 2021/2282, that an interest declared in a DOI submitted by a representative in accordance with Article 3(1) of this Regulation constitutes a conflict of interest within the meaning of Annex II thereto that is deemed incompatible with the participation in the joint work, the HTA secretariat shall invite the member of the Coordination Group or its subgroup to appoint another representative. The member may re-appoint the same representative once the conflict of interest no longer exists. 2\. If the Commission decides, in accordance with Article 28, point (b), of Regulation (EU) 2021/2282, that an interest declared in a DOI submitted by a representative in accordance with Article 3(2) of this Regulation constitutes a conflict of interest within the meaning of Annex II thereto that is deemed incompatible with the participation in the joint work, the HTA secretariat shall ensure that the representative is no longer involved in the joint work and shall inform the representative thereof. The HTA secretariat shall invite the member of the Coordination Group or its subgroup to appoint another representative. The member may re-appoint the same representative once the conflict of interest no longer exists. 3\. If the Commission decides, in accordance with Article 28, point (b), of Regulation (EU) 2021/2282, that an interest declared in a DOI submitted by a representative in accordance with Article 3(1) or (2) of this Regulation constitutes a conflict of interest within the meaning of Annex II thereto that is deemed incompatible with taking up certain roles and responsibilities in the joint work, or a conflict or potential conflict of interest in relation to the health technology developer or to the specific health technologies, the HTA secretariat shall inform the representative, the member of the Coordination Group or its subgroup and, as appropriate, the Coordination Group or its subgroups of the conflict or the potential conflict of interest of the representative and shall ensure the enforcement of the measures set out in Annex II to this Regulation. Article 7 Action with regard to conflicts or potential conflicts of interest of individual experts 1\. If the Commission decides, in accordance with Article 28, point (b), of Regulation (EU) 2021/2282, that an interest declared in a DOI submitted by an individual expert in accordance with Article 3(1) of this Regulation constitutes a conflict of interest within the meaning of Annex II thereto that is deemed incompatible with the participation in the joint work or a conflict of interest in relation to the health technology developer or to the specific health technologies, the HTA secretariat shall ensure that that individual expert is not selected to be involved in the joint clinical assessment or joint scientific consultation and shall inform the individual expert thereof. 2\. If the Commission decides, in accordance with Article 28, point (b), of Regulation (EU) 2021/2282, that an interest declared in a DOI submitted by an individual expert in accordance with Article 3(2) of this Regulation constitutes a conflict of interest within the meaning of Annex II thereto that is deemed incompatible with the participation in the joint work or a conflict of interest in relation to the health technology developer or to the specific health technologies, the HTA secretariat shall ensure that the individual expert is no longer involved in the joint clinical assessment or joint scientific consultation and shall inform the individual expert thereof. The HTA secretariat shall inform, as appropriate, the relevant subgroup, assessor and co-assessor for the joint clinical assessment or joint scientific consultation of the exclusion of the individual expert from the relevant assessment or consultation. 3\. By way of derogation from paragraph 1, where in exceptional cases, for example, for rare diseases, no individual experts free from conflicts of interests within the meaning of Annex II that have the relevant in-depth specialised expertise are available, the Commission may propose to the relevant subgroup the appropriate involvement of such individual experts in the joint work considering their conflicts of interest. The same applies where the exclusion of an individual expert in accordance with paragraph 2, would result in no involvement of a patient or a clinical expert in a joint clinical assessment or a joint scientific consultation. Article 8 Obligations of the representatives and individual experts in case of a new conflict of interest 1\. If a representative or an individual expert involved in the joint work has a new interest listed in Annex II as constituting a conflict of interest that is deemed incompatible with the participation in the joint work, they shall immediately step down from their roles and responsibilities. The representative or the individual expert shall declare that interest in a DOI submitted in accordance with Article 3(2) of this Regulation. Alternatively, they may declare the interest in writing to the HTA secretariat. 2\. If during a meeting of the Coordination Group or its subgroups a representative or an individual expert becomes aware of a new interest listed in Annex II as constituting a conflict of interest in relation to the items on the agenda, they shall immediately declare that interest to the chair or the co-chair of the Coordination Group or its subgroup and to the HTA secretariat and withdraw from the relevant part of the meeting. The representative or the individual expert shall update their DOI without undue delay. 3\. If during a joint clinical assessment or joint scientific consultation or a meeting of the Coordination Group or its subgroups a representative or an individual expert becomes aware of new circumstances in which the limitations listed in Annex II apply to them, they shall immediately inform the HTA secretariat and, as appropriate, the assessor, co-assessor, chair or the co- chair of the Coordination Group or its subgroup and withdraw from the relevant assessment, consultation or part of the meeting. 4\. If a representative or an individual expert involved in the joint work intends to be engaged in activities with a health technology developer and will therefore acquire an interest listed in Annex II as constituting a conflict of interest that is deemed incompatible with the participation in the joint work, they shall immediately declare that interest in a DOI submitted in accordance with Article 3(2) of this Regulation or in writing to the HTA secretariat irrespective of whether a contract with the health technology developer has been signed or not. Articles 6(2) and 7(2) shall apply with regard to the action to be taken. 5\. By way of derogation from paragraphs 1 to 4, where the exclusion or the withdrawal of an individual expert would result in no involvement of a patient or a clinical expert having relevant in-depth specialised expertise in a joint clinical assessment or a joint scientific consultation, the Commission may propose to the relevant subgroup the appropriate involvement of such individual experts in the joint work considering their conflicts of interest. Article 9 Obligations of the members of the Coordination Group and its subgroups Members of the Coordination Group and its subgroups shall notify the HTA secretariat in writing, if a representative has resigned or has been removed from their duties, at the latest by the day of their actual resignation or removal. Article 10 Failure to declare an interest 1\. If the Commission becomes aware of information that is not consistent with the information included in the DOI of a representative or an individual expert, it shall inform the representative or individual expert in writing and request a clarification of the situation. The representative or the individual expert shall provide the requested clarification within 14 days from the day of the notification of the request. 2\. If the representative or the individual expert does not provide the requested clarification within the period referred to in paragraph 1, the Commission may decide to exclude the representative or the individual expert from participation in the joint work until the clarification is provided and assessed by the Commission. 3\. If the requested clarification is provided, and irrespective of the assessment of the interests at issue, the Commission may exclude the representative or the individual expert from the joint work for a period up to 2 years, if the representative or the individual expert failed to declare the interest intentionally or by gross negligence. 4\. The HTA secretariat shall inform the representative, the individual expert and, as appropriate, the member of the Coordination Group or its subgroup, the Coordination Group or its subgroups of the decisions of the Commission referred to in paragraph 3 and shall ensure the enforcement of the measures imposed in those decisions. Article 11 Personal data processing 1\. The Commission shall be controller of the processing, through the HTA IT Platform, of personal data of representatives and individual experts collected under this Regulation. 2\. The categories of personal data referred to in paragraph 1 of this Article shall be the DOI and CV listed in Article 3 and Annex I, information confirmed in accordance with Article 5(1), point (b), as well as other related personal data. 3\. The DOI and CV of patients involved in joint clinical assessments and joint scientific consultations, as well as the information submitted by them in accordance with Article 4(2), shall not be made publicly available. Such documents and information shall be only made available to the Commission when performing its tasks under this Regulation with restricted access on a need- to-know basis and subject to safeguards as required by Article 10(2), point (i), of Regulation (EU) 2018/1725. Such safeguards may include in particular pseudonymisation, prevention of unauthorised access, prevention of unauthorised reading, copying, modification or deletion of personal data, as well as organisational measures ensuring that personnel authorised to process data have access only to data covered by their access authorisation, and that it is possible to verify and establish what data have been accessed, by which member of the personnel and at what time. 4\. The Commission shall keep the personal data included in DOI and CV submitted in accordance with Article 3, and information confirmed in accordance with Article 5(1), point (b), as well as other related personal data, of the representatives and individual experts only for as long as necessary for the purpose referred to in paragraph 1 of this Article and no longer than 15 years after the date on which the representatives or individual experts no longer participate in the joint work. The Commission shall review the necessity of storing the personal data every 2 years. Article 12 Entry into force and application This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. It shall apply from 12 January 2025. This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 25 October 2024. For the Commission The President Ursula VON DER LEYEN * * * (1) OJ L 458, 22.12.2021, p. 1, ELI: http://data.europa.eu/eli/reg/2021/2282/oj. (2) Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p.1, ELI: http://data.europa.eu/eli/reg/2017/745/oj). (3) Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23 October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC (OJ L 295, 21.11.2018, p. 39, ELI: http://data.europa.eu/eli/reg/2018/1725/oj). * * * ANNEX I Declaration of interests form for the participation in the joint work carried out under Regulation (EU) 2021/2282 Please answer each of the questions below. If the answer to any of the questions is ‘yes’, please provide further requested details on relevant interests, as appropriate. If you do not do so, your declaration of interests form will be considered incomplete and, therefore, you will be excluded from joint work carried out in line with Regulation (EU) 2021/2282. First name: Family name: Organisation/company (where applicable): Country: Job title in the organisation/company (where applicable): --- Type of activity (choose one or several, as appropriate): Representative in the Coordination Group Representative in the subgroup on joint clinical assessments Representative in the subgroup on joint scientific consultations Representative in the subgroup on the identification of emerging health technologies Representative in the subgroup on development of methodological and procedural guidance Patient Clinical expert Other relevant expert --- 1\. EMPLOYMENT | Q1.1. | Are you or were you employed by a health technology developer: | — | within the past 5 years in an executive role, such as president/vice president, chief executive officer, chief scientific officer, executive director/director/associate director (Question 1.1a); ---|--- — | within the past 3 years in a role involving horizontal responsibility other than executive role (Question 1.1b); ---|--- — | within the past 3 years in a role involving individual product responsibility (Question 1.1c)? ---|--- ‘ employed by a health technology developer ’ means any form of occupation, part-time or full-time, paid or unpaid, in a health technology developer. ‘ horizontal responsibility ’ means support activities for multiple health technologies across one or several therapeutic areas/full product range, such as pharmacovigillance, regulatory affairs, statistical methodology. yes | no | □ | □ Function | Time period (from… until month/year) | Name of the health technology developer | Role/area of activity | Therapeutic area(s) (where relevant) ---|---|---|---|--- | Q1.1a. | Executive role (within the past 5 years) ---|--- | | | | Q1.1b. | Horizontal responsibility other than executive role (within the past 3 years) ---|--- | | | Function | Time period (from… until month/year) | Name of the health technology developer | Name of the health technology(ies) and the respective therapeutic indication(s) ---|---|---|--- | Q1.1c. | Individual product responsibility (within the past 3 years) ---|--- | | | Q1.2. | Are you or were you within the past 3 years employed in a role involving individual product responsibility by a company or organisation, to which a health technology developer has outsourced its activities on a contractual basis, such as clinical research, regulatory affairs, health technology assessment, marketing or sales? ---|--- ‘ employed by a company or organisation ’ means any form of occupation, part- time or full-time, paid or unpaid, in a company or organisation. yes | no | □ | □ Name of the company /organisation of employment | Time period (from … until month/year) | Name of the health technology developer | Name of the health technology(ies) and the respective therapeutic indication(s) ---|---|---|--- | | | 2\. CONSULTANCY | Q2. | Do you currently, or did you within the past 3 years, provide advice to or conduct research including writing articles for a health technology developer regardless of contractual arrangements or any form of remuneration? ---|--- This question does not cover: — | advice provided to a health technology developer on behalf of a national or regional authority or body. Such activity is not to be declared; ---|--- — | employment in consultancy companies or contract research organisations providing advice to health technology developers. Such activity is to be declared under Question 1.2 (‘Employment’); ---|--- — | participation in an advisory board, steering committee, executive committee in the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a health technology developer. Such activity is to be declared under Question 3 (‘Strategic advisory role’); ---|--- — | providing presentations or training courses. Such activity is to be declared under Question 4.2 (‘Financial interests’) under the conditions specified therein; ---|--- — | conducting clinical trials, clinical investigations or performance studies where you acted as a principal investigator or investigator. Such activity is to be declared under Question 5 (‘Principal investigator and investigator’). ---|--- yes | no | □ | □ Type of consultancy | Time period (from… until month/year) | Name of the health technology developer | Name of the health technology(ies) and the respective therapeutic indication(s) ---|---|---|--- | Q2a. | Individual product related ---|--- | | Type of consultancy | Time period (from… until month/year) | Name of the health technology developer | General role/area of activity | Therapeutic area(s) (where relevant) ---|---|---|---|--- | Q2b. | Horizontal ---|--- | | | 3\. STRATEGIC ADVISORY ROLE | Q3. | Do you currently, or did you within the past 3 years, participate in a(n) (scientific) advisory board/steering committee/executive committee in the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a health technology developer, regardless of contractual arrangements or any form of remuneration? ---|--- This question does not cover: — | involvement in data monitoring committees. Such activity is to be declared under Question 5 (‘Principal investigator and investigator’); ---|--- — | non-remunerated participation in community advisory boards or other similar entities that aim at patients being able to provide their objective input to research and development of health technologies. Such activity is not to be declared. ---|--- yes | no | □ | □ Type of role | Time period (from… until month/year) | Name of the health technology developer | Name of the health technology(ies) and the respective therapeutic indication(s) ---|---|---|--- | Q3a. | Individual product related ---|--- | | Type of role | Time period (from… until month/year) | Name of the health technology developer | General role/area of activity | Therapeutic area(s) (where relevant) ---|---|---|---|--- | Q3b. | Horizontal ---|--- | | | 4\. FINANCIAL INTERESTS | Q4.1. | Do you currently have any of the following financial interests with a health technology developer: | — | (co)ownership, shares and other stocks, stock options, stock warrants, equities, bonds. This does not cover the holding of financial interests through an investment fund, pension fund or similar arrangements provided that they are diversified and independently managed; ---|--- — | intellectual property rights owned by you or of which you are directly a beneficiary? ---|--- yes | no | □ | □ Financial interest | Name of the health technology developer and/or the health technology ---|--- | | Q4.2. | Do you currently, or did you within the past 3 years, benefit from: | — | payment by a health technology developer to provide a presentation or training course, attend a conference/seminar/event; ---|--- — | reimbursement by a health technology developer of expenses incurred in relation to providing a presentation or training course, attending a conference/seminar/event? ---|--- This question does not cover: — | payment(s)/reimbursement(s) of expenses of a cumulative total value below EUR 1 000 from one health technology developer over the past 3 years. Such interests are not to be declared. ---|--- yes | no | □ | □ Financial interest | Payment/ reimbursement directly to you | Date of payment/ reimbursement | Name of the health technology developer | Therapeutic area(s) (where relevant) ---|---|---|---|--- | Yes | No | | | □ | □ 5\. PRINCIPAL INVESTIGATOR AND INVESTIGATOR | Q5. | Do you currently, or did you within the past 3 years, act as a principal investigator or an investigator in a clinical trial, observation study, clinical investigation or performace study? ---|--- yes | no | □ | □ Time period (from… until month/year) | Name of the sponsor health technology developer (where relevant) | Name of the health technology(ies) and the respective therapeutic indication(s) ---|---|--- | | 6\. LEAD MEMBER IN AN ORGANISATION/INSTITUTION RECEIVING FUNDING FROM HEALTH TECHNOLOGY DEVELOPERS | Q6. | Are you currently (co)chair, president, director, treasurer of an organisation/institution that during the current financial year or during the most recent financial year closed received direct funding from a health technology developer or several health technology developers? ---|--- This question does not cover: — | funding of national or regional authorities or bodies by fees from health technology developer. Such interests are not to be declared; ---|--- — | funding for the organisation of non-remunerated community advisory boards or other similar entities that aim at patients being able to provide their objective input to research and development of health technologies. Such interests are not to be declared. ---|--- yes | no | □ | □ Organisation/ institution | Registration number in the Transparency Register (where applicable) | Name of the health technology developer(s) | Current financial year | Most recent financial year closed ---|---|---|---|--- | | | Yes | No | Yes | No □ | □ | □ | □ 7\. INTERESTS OF IMMEDIATE FAMILY MEMBERS | Q7. | Do your immediate family members have interests referred to in Questions 1.1a, 1.1b, 1.1c, 1.2 (‘Employment’) and 4.1 (‘Financial interests’)? ---|--- ‘ immediate family member ’ means the individual’s spouse, children and parents. ‘Spouse’ includes a partner with whom the individual has a registered non marital regime. ‘ children ’ means the children that the individual and the spouse have in common, the individual’s own children and the spouse’s own children. yes | no | □ | □ Type of interest declared | Name of the health technology developer and/or the health technology ---|--- | 8\. OTHER RELEVANT INFORMATION Do you have any additional information relevant to the joint work that you would like to disclose? | yes | no ---|---|--- | □ | □ Please provide the description here (please do not provide any personal data of other individuals): * * * ANNEX II Exclusions from and limitations of the participation in the joint work based on the declared interests Declared interest | Time frame | (Co)Chair | Representative, including (co)assessor | Individual expert (patient, clinical expert, other relevant expert) ---|---|---|---|--- | 1. | EMPLOYMENT ---|--- | 1.1a. | Executive role ---|--- Current | X | X | X Within the past 5 years | XC | XT/XHTD* | XT/XHTD* | 1.1b. | Horizontal responsibility other than executive role ---|--- Current | X | X | X Within the past 3 years | XC | XT/XHTD* | XT/XHTD* | 1.1c. | Individual product responsibility ---|--- Current | X | X | X Within the past 3 years | XC | XHT | XHT | 1.2. | Employment in consultancy company or contract research organisation ---|--- Current | X | X | X Within the past 3 years | XC | XHT | XHT | 2. | CONSULTANCY ---|--- | 2a. | Individual product related ---|--- Current | X | X | X Within the past 3 years | XC | XHT | XHT | 2b. | Horizontal ---|--- Current | X | X | X Within the past 3 years | XC | XT/XHTD* | XT/XHTD* | 3. | STRATEGIC ADVISORY ROLE ---|--- | 3a. | Individual product related ---|--- Current | X | X | X Within the past 3 years | XC | XHT | XHT | 3b. | Horizontal ---|--- Current | X | X | X Within the past 3 years | XC | XT/XHTD* | XT/XHTD* | 4. | FINANCIAL INTERESTS ---|--- | 4.1. | (Co)ownership, shares etc., intellectual property rights ---|--- Current | X | X | X | 4.2. | Payment/ reimbursement of expenses ---|--- Current | X | XT/XHTD* | XT/XHTD* Within the past 3 years | RCHTD | XT/XHTD* | XT/XHTD* | 5. | PRINCIPAL INVESTIGATOR AND INVESTIGATOR ---|--- Current | XC | XHTD/XHT** | XHTD/XHT** Within the past 3 years | RCHTD/RCHT** | XHT | XHT | 6. | LEAD MEMBER IN AN ORGANISATION/INSTITUTION RECEIVING FUNDING FROM HEALTH TECHNOLOGY DEVELOPERS ---|--- Current financial year | X | XHTD | XHTD Most recent financial year closed | RCHTD | XHTD | XHTD | 7. | INTERESTS OF IMMEDIATE FAMILY MEMBERS ---|--- Current | RCHTD/RCHT*** | XHTD/XHT*** | XHTD/XHT*** Explanations Interests constituting a conflict of interest deemed incompatible with the participation in the joint work --- X | No participation in joint work Interests constituting a conflict of interest deemed incompatible with taking up certain roles and responsibilities in the joint work --- XC | Cannot be elected as chair/co-chair Interests constituting a conflict or potential conflict of interest in relation to the health technology developer or to the specific health technologies --- RCHTD | To be replaced as chair/co-chair with regard to any health technologies under assessment or comparator health technologies from the health technology developer RCHT | To be replaced as chair/co-chair with regard to specific health technologies under assessment or comparator health technologies XHTD | No involvement of the representative as (co)assessor nor in any discussions or decision making in relation to any health technologies under assessment or comparator health technologies from the health technology developer No involvement of the individual expert in joint work in relation to any health technologies under assessment or comparator health technologies from the health technology developer XHT | No involvement of the representative as (co)assessor nor in any discussions or decision making in relation to specific health technologies under assessment or comparator health technologies No involvement of the individual expert in joint work in relation to specific health technologies under assessment or comparator health technologies XT | No involvement of the representative as (co)assessor nor in any discussions or decision making in relation to health technologies under assessment or comparator health technologies from the health technology developer within the therapeutic area No involvement of the individual expert in joint work in relation to health technologies under assessment or comparator health technologies from the health technology developer within the therapeutic area XT/XHTD* | XT where the role, horizontal responsibility, presentation, training course, participation in a conference/seminar/event is/was related to a therapeutic area or several therapeutic areas XHTD where the therapeutic area cannot be identified RCHTD/RCHT** | RCHTD if clinical trial, observation study, clinical investigation or performance study was sponsored by a health technology developer RCHT if clinical trial, observation study, clinical investigation or performance study was sponsored by other means except by health technology developers XHTD/XHT** | XHTD if clinical trial, observation study, clinical investigation or performance study is/was sponsored by a health technology developer XHT if clinical trial, observation study, clinical investigation or performance study is/was sponsored by other means except by health technology developers RCHTD/RCHT*** | RCHTD in case of financial interests listed in Question 4.1, except the intellectual property rights in a health technology RCHT in case of intellectual property rights in a health technology XHTD/XHT*** | XHTD in case of financial interests listed in Question 4.1, except the intellectual property rights in a health technology XHT in case of intellectual property rights in a health technology ‘ Comparator health technology ’ means a health technology identified in the assessment scope for the joint clinical assessment finalised by the subgroup on joint clinical assessments. Comparator health technology that is no longer covered by a patent or supplementary protection is not taken into consideration for the conflict of interest management. * * * ELI:

http://data.europa.eu/eli/reg_impl/2024/2745/oj ISSN 1977-0677 (electronic edition) * * *